GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] 8th independent test on JEEP — 97.2% on a claimed 97.0%, and the trend is the interesting part — 24 comments in the full submission. View in context.
411
c/survodutide·submitted 2 years ago by u/cormac_danquah

[Lab] 8th independent test on JEEP — 97.2% on a claimed 97.0%, and the trend is the interesting part

Trial Databranch of 8 comments

Result first, context after: 8th independent test on JEEP — 97.2% on a claimed 97.0%, and the trend is the interesting part . Everything below is how it was ordered, stored and sent. Numbers, in the order they matter: 97.2% and 97.0%. Histological endpoints in this field are scored on biopsy: resolution of…

Read the full submission and all 24 comments →

This branch

8 comments, started 2 years ago
u/julia_mensa36 points·2 years ago

Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.

replysharereportpermalink
u/cold_chromatogram_only17 points·2 years ago

Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to

julia_mensa is right that biopsy and imaging endpoints are not interchangeable.

replysharereportpermalink
u/cormac_danquah7 points·2 years ago

That figure is from the obesity programme, and this thread is about the hepatic one.

replysharereportpermalink
u/elin_tamm3 points·2 years ago

That figure is from the obesity programme, and this thread is about the hepatic one.

Agreed — and the endpoint definitions are where the actual claim lives.

replysharereportpermalink
u/zeynep_villalobos1 point·2 years ago

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

replysharereportpermalink
u/georgi_adebayo1 point·2 years ago

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

replysharereportpermalink
u/paper_trail_paulavetting1 point·2 years ago

What does the tolerability table say at that dose?

replysharereportpermalink
u/chidi_demir4 points·2 years ago

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.